• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Alzheimer’s Drugs Tested In First-Ever Virtual Clinical Trial

November 3, 2022 by Deborah Bloomfield

A computer model successfully simulated a clinical trial, testing two Alzheimer’s drugs head-to-head in a first-of-its kind study.

“We’re calling this a virtual clinical trial, because we used real, de-identified patient data to simulate health outcomes,” said lead author Dr Wenrui Hao, of Penn State University, in a statement. “What we found aligns almost exactly with findings in prior clinical trials, but because we were using a virtual simulation, we had the added benefit of directly comparing the efficacy of different drugs over longer trial periods.”

Advertisement

Alzheimer’s disease is a growing public health issue. In recent years, we have seen a slew of new theories about the potential causes of the disease, plus a few notable controversies. In 2021, the US Food and Drug Administration (FDA) approved the first new Alzheimer’s drug in 18 years, aducanumab.

This new study compared aducanumab with donanemab, another promising drug currently being evaluated. Both treatments aim to remove the plaques of beta-amyloid protein that build up in the brains of patients with the disease.

The researchers built a mathematical model to predict disease trajectory in patients, using clinical and biomarker data. The doses of each drug were set to the same dosages that are used in human trials for FDA approval. The virtual trial periods were set at 78 weeks for medium-term follow-up, and 10 years for long-term follow-up.

Advertisement

The model was also used to develop personalized treatment regimens for individual virtual patients. This meant that the doses of the drugs could be adjusted to combat potential side effects, such as brain swelling and vision problems.

“Our objective was to minimize cognitive decline while also minimizing the treatment dosage to limit the corresponding side effects,” said co-author Dr Suzanne Lenhart, of the University of Tennessee, Knoxville. “Our model will give the optimal treatment level over time of the drug, but maybe even more importantly, it provides the optimal personalized treatment plan for each patient.”

Personalized medicine is likely to play an important role in future Alzheimer’s treatment. As the researchers point out, continuing uncertainty about the best way to combat the disease is “rooted in an incomplete understanding of the complex mechanisms resulting in AD [Alzheimer’s disease], and how disease trajectory and response to treatment may vary individual-to-individual.”

Advertisement

The results of the virtual trial showed that both drugs were highly successful at removing beta-amyloid plaques, corroborating findings from previous clinical studies. 

Donanemab, the newer drug that does not yet have FDA approval, performed slightly better than aducanumab at slowing cognitive decline over 10 years, but neither drug had a large effect. The advantage of the virtual trial is that these results were obtained much more quickly than they could have been using traditional human trials.

“With over 10 anti-amyloid therapies in development, an important question is which one is better,” said co-author Dr Jeffrey Petrella, of Duke University. “It often takes tens of millions of dollars and many years to do a head-to-head comparison of drugs. Our study showed that the effect of these two anti-amyloid drugs on slowing cognitive decline is actually quite modest – and if given late in life, barely detectable.”

Advertisement

In the future, the researchers hope to further refine the model and apply it to different classes of Alzheimer’s drugs, as well as combination therapies. “We’ve shown that this type of model can work,” said Petrella. “I envision it being used as a precision tool to enhance actual clinical trials, optimizing dosages and combinations of drugs for individual patients.”

The study is published in PLOS Computational Biology.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Who to blame for Taliban takeover? Former Afghan envoy points finger at Kabul
  2. Lounge’s new app aims to reimagine the office for the remote work era
  3. FOMC teases start of taper “soon”
  4. Review: The Surface Pro 8 with Windows 11 is fast and fresh

Source Link: Alzheimer's Drugs Tested In First-Ever Virtual Clinical Trial

Filed Under: News

Primary Sidebar

  • “Nobody Expected This”: Earth’s Rotation Will Speed Up Tomorrow, Bucking The Downward Trend
  • Chimps Are Sticking Grass In Their Ears And Rears As They Embrace “Pointless” Fad
  • Hui Te Rangiora: Old Māori Legend Suggests They May Have Discovered Antarctica 1,000 Years Before Europeans
  • “Potential Impact On Saturn”: Astronomers Appeal For Help As Video Appears To Show Object Hitting The Gas Giant
  • What Is Prosopometamorphopsia? The “Exceedingly Rare” Condition That Made A Patient See Faces As Dragons
  • Are We In An Enormous Void? It Could Explain What’s Wrong With Our Model Of The Universe
  • Woylies Boing Back Into Western Australia Thanks To Groundbreaking Wildlife Project
  • North America’s Oldest Pterosaur And Turtle Fossils Found In Arizona’s Petrified Forest
  • Proposed “Dark Dwarfs” Near The Galactic Center Could Reveal The Nature Of Dark Matter
  • Watch: 18-Kilometer-High Ash Cloud Looms Over Indonesia’s Mount Lewotobi Laki Laki After “Explosive” Eruption
  • “ShipGoo001”: Mystery Of Entirely New Lifeform Discovered Coating A Great Lakes Ship
  • Rare White Humpback Whale Calf Filmed By Drone Off Australia’s East Coast
  • Who Was Buried At Cave Of Salome: A Female Disciple, Jesus’ Midwife, Or A Princess?
  • “Hidden” Changes To US Health Data Swapping “Gender” For “Sex” Spark Fears For Public Trust
  • Easter Island Was Never As Isolated As We Thought – Study Puts That “Strange Argument” To Bed
  • If Birds Are Dinosaurs, Why Are None As Big As T. Rexes?
  • Psychologists Demonstrate Illusion That Could Be Screwing Up Our Perception Of Time
  • Why Are So Many Enormous Roman Shoes Being Discovered At Hadrian’s Wall?
  • Scientists Think They’ve Pinpointed Structural Differences In Psychopaths’ Brains
  • We’ve Found Our Third-Ever Interstellar Visitor, Orcas Filmed Kissing (With Tongues) In The Wild, And Much More This Week
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version